Agoracom: Small Cap Investment - Zenith Epigenetics - Pfizer vs J&J

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Pfizer vs J&J - Nonmetastatic prostate cancer

posted on Feb 06, 2018 09:54AM

Hmmm...seems like folks are living longer while taking Xtandi and its rival. However, no mention of Zen3694 in this article. Does this imply J&J and Pfizer may not need Zenith after all?

https://endpts.com/pfizer-vs-jj-researchers-are-duking-it-out-for-the-championship-title-in-nonmetastatic-prostate-cancer/?utm_medium=email&utm_campaign=Tuesday%20February%206%202018&utm_content=Tuesday%20February%206%202018+CID_886a8ae48be18ba90512b3a3742eaa17&utm_source=ENDPOINTS%20emails&utm_term=Pfizer%20vs%20JJ%20Researchers%20are%20duking%20it%20out%20for%20the%20championship%20title%20in%20nonmetastatic%20prostate%20cancer